Upper Gastrointestinal (GI) Morbidity and Gastric Acid–Reducing Agent (GARA) Use Among Oncolytic-Treated Patients with Non-Hodgkin Lymphomas: Nursing Perspective Insights
To evaluate the epidemiology of upper GI morbidity, peptic ulcer risk, and prescription GARA use among patients with MCL or CLL/SLL and provide the nursing perspective on GARA use in oncology patient care.
Patient-Reported Outcomes from the Phase 3, Randomized Study of Acalabrutinib with or without Obinutuzumab versus Chlorambucil plus Obinutuzumab for Treatment-Naive Chronic Lymphocytic Leukemia (ELEVATE-TN)
P Walker , JP Sharman, W Jurczak, T Munir, V Banerji, S Coutre, JA Woyach, G Salles, WG Wierda, P Patel, MH Wang, U Emeribe, E Flood, JC Byrd, P Ghia
Impact of Age on Efficacy and Safety of Relugolix: A Subgroup Analysis from the Randomized, Phase 3 HERO Study versus Leuprolide in Men with Advanced Prostate Cancer
Michael S. Cookson, MD, MMHC, Neal D. Shore, MD, Daniel J. George, MD, Hideyuki Akaza, MD, Daniel R. Saltzstein, MD, Ronald Tutrone, MD, Alberto Bossi, MD, Bruce Brown, MD, Bryan Selby, MS, Sophia Lu, PhD, Jackie Walling, MBChB, PhD, Bertrand Tombal, MD, PhD, Fred Saad, MD
Tomasz M. Beer, Charles H. McDonnell, III, Lincoln Nadauld, Minetta C. Liu, Eric A. Klein, Robert Reid, Catherine R. Marinac, Karen C. Chung, Margarita Lopatin, Eric T. Fung, Deborah Schrag
Characterization of Adverse Reactions in Patients with Advanced Endometrial Cancer (aEC) Receiving Lenvatinib + Pembrolizumab (Study 309/KEYNOTE-775): Nurse Roles in Patient Education and Adverse-Reaction Management